Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00833898
First received: January 30, 2009
Last updated: November 6, 2015
Last verified: November 2015
Results First Received: June 8, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Investigator);   Primary Purpose: Treatment
Condition: Hematopoietic/Lymphoid Cancer
Interventions: Device: Paced respiration as part of PEPRR
Behavioral: PEPRR

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Caregivers and their patients were recruited consecutively between 11/2008 and 4/2012 during pre-transplant screening of all Allo-HSCT patients and their caregivers at a single site (Presbyterian St. Luke’s Medical Center, Denver, CO).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
149 patient-caregiver dyads were consented (298 participants) and 148 dyads were randomized. 1 dyad (2 participants) did not meet the inclusion criteria.

Reporting Groups
  Description
Caregiver Control Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
Caregiver Intervention Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), includes one-on-one psychoeducation, stress management intervention, with paced respiration.

Participant Flow:   Overall Study
    Caregiver Control   Caregiver Intervention
STARTED   74   74 
Month 1 (Post Transplantation)   72   74 
Month 3 (Post Transplantation)   66   64 
Month 6 (Post Transplantation)   59   54 
Month 12 (Post Transplantation)   50   50 
COMPLETED   34   38 
NOT COMPLETED   40   36 
Withdrawal by Subject                33                27 
Lost to Follow-up                7                7 
Patient did not receive transplant                0                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Caregiver Control Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
Caregiver Intervention Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), includes one-on-one psychoeducation, stress management intervention, with paced respiration.
Total Total of all reporting groups

Baseline Measures
    Caregiver Control   Caregiver Intervention   Total
Overall Participants Analyzed 
[Units: Participants]
 74   74   148 
Age 
[Units: Years]
Mean (Standard Deviation)
 54.8  (12.355)   52.2  (12.169)   53.5  (12.285) 
Gender [1] 
[Units: Participants]
     
Female   56   56   112 
Male   17   18   35 
[1] For Caregiver Control gender information, participant did not reported their gender (n = 1).
Race/Ethnicity, Customized 
[Units: Participants]
     
Caucasian (not Latino/Hispanic)   68   65   133 
Black/African-American (not Latino/Hispanic)   2   0   2 
Asian/Oriental/Pacific Islander   0   1   1 
Latino/Hispanic/Mexian-American   1   6   7 
Other   1   1   2 
Unknown or Not Reported   2   1   3 
Region of Enrollment 
[Units: Participants]
     
United States   74   74   148 
Annual income [1] 
[Units: Participants]
     
< 25,000   13   11   24 
25,000-44,999   15   14   29 
45,000-64,999   11   15   26 
> 65,000   31   29   60 
Unknown or Not Reported   4   5   9 
[1] Income in dollars
Relationship to patient 
[Units: Participants]
     
Spouse/partner   46   57   103 
Parent   19   8   27 
Other   8   8   16 
Unknown or Not Reported   1   1   2 
Employment Status (Before Caregiving) 
[Units: Participants]
     
Full-time   35   36   71 
Part-time   11   13   24 
Unemployed   8   7   15 
On leave   1   2   3 
Retired   16   13   29 
Unknown or Not Reported   3   3   6 
Employment Status (During Caregiving) 
[Units: Participants]
     
Full-time   16   19   35 
Part-time   7   10   17 
Unemployed   14   8   22 
On leave   17   19   36 
Retired   15   15   30 
Unknown or Not Reported   5   3   8 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Behavioral - Stress Level as Measured by the Perceived Stress Scale (PSS)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

2.  Primary:   Physiological - Cortisol Awakening Response (CAR)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

3.  Secondary:   Depression Measured by the Center for Epidemiological Studies Depression Scale (CESD)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

4.  Secondary:   State Anxiety as Measured by the Spielberger State-Trait Anxiety Inventory (STAI)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

5.  Secondary:   Total Mood Disturbance (TMD) Score Using the Profile of Mood States (POMS)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

6.  Secondary:   Stress as Measured by Caregiver Burden Using the Caregiver Reaction Assessment (CRA)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

7.  Secondary:   Sleep as Assessed by the Pittsburgh Sleep Quality Inventory (PSQI) Total Score   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

8.  Secondary:   Mental Component Summary Via the Short-Form 36-Item Health Survey Version 2.0 (SF-36M)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

9.  Secondary:   Physical Component Summary Via the Short-Form 36-Item Health Survey Version 2.0 (SF-36P)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

10.  Secondary:   Stress as Measured by the Impact of Events Scale (IES)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

11.  Secondary:   The Slope of the Diurnal Decline in Salivary Cortisol (SlopeC)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

12.  Secondary:   The Slope of the Diurnal Decline (SlopeD) in Salivary Dehydroepiandrosterone (DHEA)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

13.  Secondary:   Area Under the Curve for Salivary Cortisol (AUCc)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

14.  Secondary:   Area Under the Curve for Salivary DHEA (AUCd)   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

15.  Secondary:   Host Defense Assessed by Natural Killer (NK) Cell Cytotoxicity   [ Time Frame: Baseline (prior to transplant), 1 and 3 post transplant ]

16.  Secondary:   Plasma C-reactive Protein (CRP)   [ Time Frame: Baseline (prior to transplant) and 3 post transplant ]

17.  Secondary:   Plasma Inflammatory Marker Interleukin 1 Beta (IL-1 Beta)   [ Time Frame: Baseline (prior to transplant) and 3 post transplant ]

18.  Secondary:   Plasma Inflammatory Marker Interleukin 6 (IL-6)   [ Time Frame: Baseline (prior to transplant) and 3 post transplant ]

19.  Secondary:   Plasma Inflammatory Marker Interleukin 4 (IL-4)   [ Time Frame: Baseline (prior to transplant) and 3 post transplant ]

20.  Secondary:   Plasma Inflammatory Marker Interleukin 10 (IL-10)   [ Time Frame: Baseline (prior to transplant) and 3 post transplant ]

21.  Secondary:   Plasma Inflammatory Marker Tumor Necrosis Factor (TNF)   [ Time Frame: Baseline (prior to transplant) and 3 post transplant ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Mark L. Laudenslager, PhD
Organization: University of Colorado Denver
phone: 303-724-9279
e-mail: biel@ucdenver.edu


Publications of Results:
Other Publications:

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00833898     History of Changes
Other Study ID Numbers: 08-0303
1R01CA126971-01A1 ( US NIH Grant/Contract Award Number )
Study First Received: January 30, 2009
Results First Received: June 8, 2015
Last Updated: November 6, 2015
Health Authority: United States: Institutional Review Board